SonoVue er kontraindiceret til patienter for nylig indtruffen akut koronarsyndrom eller klinisk ustabil iskæmisk hjertesygdom, inklusiv: udviklingende eller igangværende myokardieinfarkt, typisk angina i hvile indenfor de sidste 7 dage, signifikant forværring af hjertesymptomer indenfor de sidste 7 dage, for nylig foretaget koronararterie intervention eller andre faktorer der antyder klinisk ustabilitet (f. eks. for nylig forværring af EKG, laboratorie eller kliniske fund) akut hjerteinsufficiens, klasse III/ IV hjerteinsufficiens og alvorlig arrythmi.
SonoVue is contraindicated for use in patients with recent acute coronary syndrome or clinically unstable ischaemic cardiac disease, including: evolving or ongoing myocardial infarction, typical angina at rest within last 7 days, significant worsening of cardiac symptoms within last 7 days, recent coronary artery intervention or other factors suggesting clinical instability (for example, recent deterioration of ECG, laboratory or clinical findings), acute cardiac failure, Class III/ IV cardiac failure, or severe rhythm disorders.